Percutaneous Endoluminal Benign Biliary Laser (PEBBL)

Percutaneous Endoscopic Laser Incision for Benign Biliary Strictures: Prospective Evaluation of Safety and Efficacy

This study is being done to evaluate the safety and efficacy of Percutaneous transhepatic cholangioscopic (PTCS) laser incision as an ancillary therapy to traditional approaches such as balloon dilation and large drain placement for Benign Biliary Strictures (BBS).

Narrowing or blockage of the bile ducts (biliary stricture) is a difficult to treat medical condition that leads to life-threatening complications. Treatment usually involves multiple procedures or surgeries spanned over months or years, and in many cases, leads to the need for a life-long tube that drains bile fluid outside of the body and into a bag. PTCS laser incision is a promising new treatment for bile duct strictures. The procedure is performed by an Interventional Radiologist who uses a tiny camera (endoscope) and a laser through a small hole in the skin to open up the blocked or narrowed duct. This allows bile to flow freely where it is supposed to go (without a tube) so that it does not backup up and cause life-threatening problems. Based on early experience from patients who have had this procedure done, it appears to be safe and effective, and may lead to needing fewer procedures over time, with the possibility of living without a tube or drain. The main goal of this study is to confirm the safety and efficacy of PTCS laser incision in a series of patients with benign biliary strictures who would otherwise receive standard treatment with long-term biliary tube drainage.

Study Overview

• Status: Recruiting
• Conditions: Benign Biliary Strictures With Current or Prior Biliary Obstruction
• Intervention / Treatment: Procedure: Percutaneous transhepatic cholangioscopic (PTCS) laser incision

Detailed Description

PTCS-guided holmium laser incision is a promising new adjuvant treatment for benign biliary strictures. Real-time monitoring under direct endoscopic visualization provides an invaluable opportunity for Interventional Radiologists to safely perform targeted diagnosis and treatment within the biliary system. Despite limited literature on the subject, there are several potential advantages of bringing cholangioscopic laser incision to the Interventional Radiology (IR) suite.

First, management of biliary strictures and their sequelae is commonplace in daily IR practice. With increasing sophistication of modern therapeutics including ablation, lithotripter, stent and retrieval devices, there is increasing risk to using fluoroscopy alone to perform complex interventions in a three-dimensional space. Endoscopy allows real-time monitoring of treatment progress and potential complications. For example, an operator using fluoroscopy could not identify iatrogenic haemobilia as readily as an operator using endoscopy, and delayed recognition of such a complication could have lethal consequences. Fortunately, hemorrhagic complications encountered in the IR suite can be treated by trans-arterial embolization. Endoscopic visualization also allows an operator to more precisely characterize the etiology, extent, and other specific features of a focal narrowing within the bile ducts, thus facilitating a more targeted and patient-specific approach to diagnosis and treatment. Conversely, a filling defect seen on conventional cholangiography is nonspecific and can result in an indeterminant biopsy or lead to inappropriate treatment.

Second, PTCS-guided laser incision can improve clinical outcomes and potentially be a definitive treatment option for patients with recalcitrant BBS who otherwise require life-long percutaneous drainage. Unlike mechanical dilation techniques such as balloon cholangioplasty and stenting, the holmium laser addresses the root cause of stricture by incising excess fibrotic intraluminal tissue and restoring patency to the native bile duct, while also eliminating the need for an indwelling device that can become a nidus for infection. In contrast to radiofrequency (RF) ablation or the neodymium laser, the holmium laser's short depth of penetration and selective wavelength for water absorption results in precise tissue dissection by way of vaporization, with minimal thermal damage to surrounding tissues. This results in less inflammation and trauma to the bile ducts, which are the major culprits of re-stenosis. Additionally, the device can be employed simultaneously for lithotripsy of concomitant biliary stones which must be removed at the time of intervention to prevent cholangitis and stricture recurrence.

Third, PTCS-guided laser incision has the potential to reduce patient morbidity and improve quality of life. By decreasing the total number of interventions and amount of time patients require a drainage catheter or other indwelling device, a decrease in cumulative procedural and stricture-related complications would likewise be expected. In contrast to 1 or 2 PTCS sessions, standard protocols involve multiple interventions over the course of several months, during which time patients are expected to self-manage a biliary drainage bag and continuously monitor for signs and symptoms of cholangitis and elevated bilirubin. Following a capping trial, still some 20-30% of patients develop recurrent stricture, many of whom have no other option but to continue indefinitely with a drainage tube while carrying a life-long risk of recurrent cholangitis and other obstructive phenomena. The improved efficiency of PTCS-guided laser incision also implicates a potential to decrease procedure-related costs, use of hospital and departmental resources, and radiation exposure to patients. In the past, the high overhead cost of reusable endoscopes prohibited most IR groups from adopting endoscopy. However, the development of new disposable low-profile devices has eliminated the financial barrier to entry for IR-operated endoscopy and may yield cost savings over time with less angiography suite usage.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Aniket Joglekar, MD; Phone Number: 310-948-8026; Email: ajoglekar@mednet.ucla.edu

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • University of California Los Angeles
      • Contact: Aniket Joglekar, MD; Phone Number: 310-948-8026; Email: ajoglekar@mednet.ucla.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients with a diagnosis of Benign Biliary Strictures (BBS)
2. Clinical and/or laboratory evidence of biliary obstruction (current or prior)
3. Age 18 years or older at the time of intervention

Exclusion Criteria:

1. Patients with a diagnosis of malignant biliary stricture at the time of enrollment
2. Patients who are subsequently diagnosed with malignant biliary stricture during the study period
3. Liver transplantation within the last 90 days
4. Active cholangitis or sepsis
5. Emergent need for biliary decompression
6. Patients with a diagnosis of primary sclerosing cholangitis with presence of 3 or more strictured segments
7. Patients with a life-expectancy of less than 36 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Patients with benign biliary strictures; Patients with benign biliary strictures with current or prior biliary obstruction, who would otherwise receive standard treatment with long-term biliary tube drainage.	Procedure: Percutaneous transhepatic cholangioscopic (PTCS) laser incision; Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Post Procedure Adverse Events	Safety evaluated by cumulative rates of post-interventional complications after PTCS-guided laser incision.; Complications will be reported according to the Society of Interventional Radiology Adverse Event (AE) classification system.; Safety will be reported as 30-day composite of all post-procedure AEs.; Complications will be further qualified and quantified by AE severity category and individual AE types.	Up to 24 months
Feasibility of Procedure	Feasibility evaluated by technical success of PTCS-guided laser incision. a. Technical success defined as endoscopic and cholangiographic evidence of improved patency at the time of intervention.	Up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Bile Duct Patency	Primary bile duct patency evaluated as mean time to first stricture recurrence.; Stricture recurrence will be defined as clinical and/or radiographic evidence of biliary occlusion requiring additional therapy.; The date of PTCS or post-intervention biliary catheter removal will mark the time of initiation.	Up to 24 months
Tube-Free Survival	Tube-free survival evaluated as cumulative time survived without a biliary device during the study period.; Duration of time that patients require a biliary catheter or stent during follow-up period will be subtracted from the 12-month total.; If a device is subsequently removed, tube-free survival time will continue to be accrued up to 12 months post-treatment.	Up to 12 months
12-Month Cumulative Complications	12-month cumulative complications from laser treatment or recurrent biliary disease. a. Composite of all PTCS- and stricture-related AEs during the 12-month follow-up period.	Up to 12 months

Collaborators and Investigators

• Sponsor: University of California, Los Angeles
• Collaborators: Boston Scientific Corporation
• Investigators: Principal Investigator: Ravi N Srinivasa, MD, University of California, Los Angeles

Study record dates

Study Major Dates

• Study Start (Anticipated): October 10, 2022
• Primary Completion (Anticipated): October 10, 2025
• Study Completion (Anticipated): October 10, 2026

Study Registration Dates

• First Submitted: September 30, 2022
• First Submitted That Met QC Criteria: September 30, 2022
• First Posted (Actual): October 5, 2022

Study Record Updates

• Last Update Posted (Actual): October 12, 2022
• Last Update Submitted That Met QC Criteria: October 7, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Constriction, Pathologic
• Other Study ID Numbers: 21-001910

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No